Rohitas Deshmukh

Dr. Rohitas Deshmukh

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
RHRanjit Kumar Harwansh
Ranjit Kumar Harwansh
RDRohitas Deshmukh
Rohitas Deshmukh
ARAkhlaquer Rahman
Akhlaquer Rahman

18 January 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AGAkash Garg
Akash Garg
RARutvi Agrawal
Rutvi Agrawal
CCChetan Singh Chauhan
Chetan Singh Chauhan
RDRohitas Deshmukh
Rohitas Deshmukh

1 April 2010 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
SDSwarnali Das
Swarnali Das
PSPreeti K. Suresh
Preeti K. Suresh
RDRohitas Deshmukh
Rohitas Deshmukh

4 April 2014 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
BMBalakrishnan Muthuraj
Balakrishnan Muthuraj
RDRohitas Deshmukh
Rohitas Deshmukh
VTVishal Trivedi
Vishal Trivedi
PIParameswar Krishnan Iyer
Parameswar Krishnan Iyer

26 September 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MKMahesh Kumar
Mahesh Kumar
TVTarun Virmani
Tarun Virmani
GKGirish Kumar
Girish Kumar
RDRohitas Deshmukh
Rohitas Deshmukh
ASAshwani Sharma
Ashwani Sharma
Pedro FontePedro Fonte
Pedro Fonte
The World Health Organization identifies tuberculosis (TB), caused by Mycobacterium tuberculosis, as a leading infectious killer. Although conventional treatments for TB exist, they come with challenges such as a heavy pill regimen, prolonged treatment duration, and a strict schedule, leading to multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. The rise of MDR strains endangers future TB control. Despite these concerns, the hunt for an efficient treatment continues. One breakthrough has been the use of nanotechnology in medicines, presenting a novel approach for TB treatment. Nanocarriers, such as lipid nanoparticles, nanosuspensions, liposomes, and polymeric micelles, facilitate targeted delivery of anti-TB drugs. The benefits of nanocarriers include reduced drug doses, fewer side effects, improved drug solubility, better bioavailability, and improved patient compliance, speeding up recovery. Additionally, nanocarriers can be made even more targeted by linking them with ligands such as mannose or hyaluronic acid. This review explores these innovative TB treatments, including studies on nanocarriers containing anti-TB drugs and related patents.

16 August 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RDRohitas Deshmukh
Rohitas Deshmukh
PSPranshul Sethi
Pranshul Sethi
BSBhupendra Singh
Bhupendra Singh
JSJailani S
Jailani S
Sagar SalaveSagar Salave
Sagar Salave
AKArun Kumar
Arun Kumar
Preclinical and clinical studies have demonstrated that precision therapy has a broad variety of treatment applications, making it an interesting research topic with exciting potential in numerous sectors. However, major obstacles, such as inefficient and unsafe delivery systems and severe side effects, have impeded the widespread use of precision medicine. The purpose of drug delivery systems (DDSs) is to regulate the time and place of drug release and action. They aid in enhancing the equilibrium between medicinal efficacy on target and hazardous side effects off target. One promising approach is biomaterial-assisted biotherapy, which takes advantage of biomaterials’ special capabilities, such as high biocompatibility and bioactive characteristics. When administered via different routes, drug molecules deal with biological barriers; DDSs help them overcome these hurdles. With their adaptable features and ample packing capacity, biomaterial-based delivery systems allow for the targeted, localised, and prolonged release of medications. Additionally, they are being investigated more and more for the purpose of controlling the interface between the host tissue and implanted biomedical materials. This review discusses innovative nanoparticle designs for precision and non-personalised applications to improve precision therapies. We prioritised nanoparticle design trends that address heterogeneous delivery barriers, because we believe intelligent nanoparticle design can improve patient outcomes by enabling precision designs and improving general delivery efficacy. We additionally reviewed the most recent literature on biomaterials used in biotherapy and vaccine development, covering drug delivery, stem cell therapy, gene therapy, and other similar fields; we have also addressed the difficulties and future potential of biomaterial-assisted biotherapies.